坐骨神經痛市場規模、佔有率和成長分析：按疾病類型、藥物類別、給藥途徑、分銷管道和地區 - 2025-2032 年行業預測

2023年全球坐骨神經痛市場規模為81.8億美元，從2024年的86.5億美元成長到2032年的134.7億美元，在預測期間（2025-2032年）預計複合年成長率為5.7%。

預計未來幾年全球坐骨神經痛市場將顯著成長，這主要是由於與久坐生活方式、人口老化和脊椎疾病快速增加相關的坐骨神經痛病例數量不斷增加。診斷技術和治療方法的創新，提高了診斷的準確性和管理的有效性。此外，人們對早期療育和復健需求的認知不斷提高正在推動市場擴張。然而，挑戰依然存在，包括高昂的治療費用、某些地區先進醫療保健系統的使用機會有限以及與外科手術相關的風險。儘管存在這些障礙，但向微創技術的轉變、新治療藥物的推出以及對個人化治療解決方案日益成長的需求預計將推動全球坐骨神經痛市場的發展。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 抑制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 監管環境
• 技術評估
• 專利分析

坐骨神經痛市場規模：依疾病類型分類

• 市場概況
• 急性坐骨神經痛
• 慢性坐骨神經痛
• 其他

坐骨神經痛市場規模：依藥物類別

• 市場概況
• 非類固醇消炎劑
• 口服類固醇
• 抗驚厥藥
• 三環抗憂鬱藥物
• 鴉片類止痛藥
• 其他

坐骨神經痛市場規模：依給藥途徑分類

• 市場概況
• 口服
• 注射

坐骨神經痛市場規模：依分銷管道分類

• 市場概況
• 醫院藥房
• 零售藥房
• 網路藥房

坐骨神經痛市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2022-2024）

主要企業簡介

• Medtronic plc（Ireland）
• Johnson & Johnson（USA）
• Zimmer Biomet Holdings, Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sanofi SA（France）
• Novartis International AG（Switzerland）
• Bristol-Myers Squibb Company（USA）
• Merck & Co., Inc.（USA）
• Zynex Inc.（USA）
• Sorrento Therapeutics, Inc（USA）
• Hikma Pharmaceuticals PLC（UK）
• Viatris Inc.（USA）
• Boston Scientific Corporation（USA）
• Abbott Laboratories（USA）
• Stryker Corporation（USA）
• GlaxoSmithKline plc（UK）
• AstraZeneca plc（UK）
• Eli Lilly and Company（USA）
• Bristol-Myers Squibb Company（USA）

結論和建議

Global Sciatica Market size was valued at USD 8.18 billion in 2023 and is poised to grow from USD 8.65 billion in 2024 to USD 13.47 billion by 2032, growing at a CAGR of 5.7% during the forecast period (2025-2032).

The global sciatica market is poised for substantial growth in the upcoming years, primarily due to a rise in sciatica cases linked to sedentary lifestyles, an aging demographic, and a surge in spinal disorders. Innovations in diagnostic technologies and treatment options are enhancing diagnosis accuracy and management effectiveness. Furthermore, heightened awareness of the need for early intervention and rehabilitation is propelling market expansion. However, challenges persist, including high treatment costs, restricted access to advanced healthcare systems in some areas, and risks associated with surgical procedures. Despite these hurdles, the shift toward minimally invasive techniques, the introduction of new therapeutics, and a growing appetite for personalized treatment solutions are anticipated to invigorate the global sciatica market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sciatica market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Sciatica Market Segmental Analysis

Global Sciatica Market is segmented by Disease Type, Drug Class, Route of Administration, Distribution Channel and region. Based on Disease Type, the market is segmented into Acute Sciatica, Chronic Sciatica and Others. Based on Drug Class, the market is segmented into Nonsteroidal Anti-Inflammatory Drugs, Oral Steroids, Anticonvulsant Agents, Tricyclic Antidepressants, Opioid Analgesics and Others. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Sciatica Market

A significant factor propelling the global sciatica market is the widespread lack of awareness and subsequent underdiagnosis of the condition. Contributing elements include sedentary lifestyles, poor posture, rising obesity rates, and an aging demographic, all of which have led to an increased prevalence of sciatica cases. As awareness grows and more individuals seek proper diagnosis and treatment, there is a heightened demand for effective diagnostic methods, therapeutic interventions, and pain management options. This growing need plays a crucial role in driving the overall expansion of the market and underscores the importance of addressing this overlooked health issue.

Restraints in the Global Sciatica Market

One significant challenge facing the global sciatica market is the prevalent lack of awareness and underdiagnosis associated with the condition. Many individuals experiencing sciatica symptoms are often unaware of their significance, which results in delayed medical intervention and treatment. Additionally, restricted access to healthcare services, particularly in rural regions, exacerbates the issue, restricting timely diagnosis and effective management of sciatica. Enhancing public knowledge about sciatica and improving healthcare infrastructure is crucial to alleviating this restraint. By fostering greater awareness and accessibility, the market can better serve individuals in need and contribute to improved health outcomes for sciatica patients.

Market Trends of the Global Sciatica Market

A prominent trend in the global sciatica market is the rising preference for minimally invasive procedures to address sciatic pain. Treatments such as endoscopic discectomy and percutaneous decompression are increasingly favored over traditional surgeries due to their numerous advantages, including smaller incisions, decreased tissue damage, and shortened recovery times. This shift is largely driven by patient demand for quicker rehabilitation and better overall outcomes, alongside a notable reduction in the risk of complications often associated with invasive surgeries. Consequently, both healthcare providers and patients are gravitating towards these innovative, less invasive options, significantly propelling growth in the global sciatica market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Technology Assessment
• Patent Analysis

Global Sciatica Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Acute Sciatica
• Chronic Sciatica
• Others

Global Sciatica Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Nonsteroidal Anti-Inflammatory Drugs
• Oral Steroids
• Anticonvulsant Agents
• Tricyclic Antidepressants
• Opioid Analgesics
• Others

Global Sciatica Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable

Global Sciatica Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Sciatica Market Size & CAGR (2025-2032)

• North America (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zimmer Biomet Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zynex Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorrento Therapeutics, Inc (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations